NCT01002703 - Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2014

Conditions

Multiple Myeloma

Interventions

DRUG

Lenalidomide, Bendamustine, Prednisone

During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.

Trial Locations (1)

04103

RECRUITING

University of Leipzig, Leipzig